Business
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177 AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc.
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"Company eligible to receive Priority Review Voucher upon FDA approval of ACN00177\n\n\nAUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine which leads to a wide range of life-altering complications and reduced life expectancy. ACN00177 is a novel engineered human enzyme therapy designed to lower the total level of homocysteine in the plasma. Aeglea initiated a Phase 1/2 clinical trial earlier this year to investigate ACN00177 for the treatment of Homocystinuria. \n\"Homocystinuria is a serious and progressive disease that significantly impacts the quality of life of patients – with a high risk of life threatening blood clots, severe vision issues, skeletal abnormalities, developmental delay and intellectual disability,\" said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. \"There is a significant need for new and better therapies for Homocystinuria patients given the lack of effective treatment options for many patients. The Rare Pediatric Disease Designation speaks to the significant impact of this disease beginning in childhood and is an important incentive in promoting drug development to improve outcomes in this patient population.\"\nThe FDA grants rare pediatric disease designation for diseases with serious or life-threatening manifestations that primarily affect fewer than 200,000 people in the United States and who are less than 18 years old. If a Biologics License Application (BLA) for the treatment of Homocystinuria is approved by the FDA, Aeglea may be eligible to receive a Priority Review Voucher (PRV), which can be redeemed to obtain priority review for any subsequent marketing application or may be sold or transferred. This program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.\nAbout ACN00177 in Homocystinuria\nAeglea is developing ACN00177 for the treatment of patients with cystathi...